التفاصيل البيبلوغرافية
| العنوان: |
Prevalence and Clinical Significance of FLT3 Mutation Status in Acute Myeloid Leukemia Patients: A Multicenter Study. |
| المؤلفون: |
Cuervo-Sierra, Jorge1, Jaime-Pérez, José Carlos1 carjaime@hotmail.com, Martínez-Hernández, Ramón A.1, García-Sepúlveda, Ricardo D.1, Sánchez-Cárdenas, Mónica1, Gómez-Almaguer, David1, Ortíz-López, Rocío2, Villarreal-Villarreal, César D.1, Ruiz-Arguelles, Guillermo J.3, Ruiz-Delgado, Guillermo3, Lutz-Presno, Julia3, Garcés-Eisele, Javier3,4, Ignacio-Ibarra, Gregorio5,6, Muciño-Hernández, Gabriel5,7, Arana-Trejo, Rosa M.5,7, Jiménez-Mejia, Angélica M.8, Vásquez-Palacio, Gonzalo8 |
| المصدر: |
Archives of Medical Research. Apr2016, Vol. 47 Issue 3, p172-179. 8p. |
| مصطلحات موضوعية: |
*GENETIC mutation, *ACUTE myeloid leukemia, *POLYMERASE chain reaction, *HEMOGLOBINS, *PATIENTS, *PROGNOSIS |
| مستخلص: |
Background and Aims FLT3-ITD mutations in acute myeloid leukemia (AML) are associated with a poor prognosis. In Latin America, little epidemiological data exist about these mutations and their influence on clinical evolution and prognosis. Standardization and well-established clinical correlation make FLT3 mutational analysis by molecular methods an invaluable tool to decide among treatment options and to determine AML prognosis. Methods We assessed the prevalence of FLT3-ITD mutations in 138 patients with AML at four hematology referral centers from Mexico and Colombia. Molecular methods based on polymerase chain reaction (PCR) were employed for determining FLT3-ITD status. Results Mutations were present in 28 patients indicating a prevalence of 20.28%. Median age was 47 years (5–96). The FLT3 mutation positive group was older, had higher WBC and hemoglobin values and lower platelet counts but without statistical significance. A not previously described mutation in the FLT3 gene was found in one patient involving a nucleotide exchange of timine for cytosine at the 66608 position. A high mortality was found in the FLT3-mutated group, 67.8 vs. 42.72% in the non-mutated group and median survival was 4.9 months vs. 20.4 months, p = 0.009. A mutated FLT3 did not confer poor prognosis to those with M3 AML. The mutated FLT3 population had poor overall survival (OS) despite hematoprogenitor stem cell transplantation (HSCT). Conclusion Prevalence of FLT3-ITD mutation in AML was present in a proportion comparable to other populations and, when present, was associated with a very poor prognosis. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
